Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT01264887
Previous Study | Return to List | Next Study

Tapentadol in Chronic Malignant Tumour Related Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01264887
Recruitment Status : Terminated (Administrative reasons)
First Posted : December 22, 2010
Results First Posted : June 22, 2015
Last Update Posted : November 4, 2019
Information provided by (Responsible Party):
Grünenthal GmbH

Brief Summary:
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain. In the United States the prolonged-release formulation is also referred to as the extended-release formulation.

Condition or disease Intervention/treatment Phase
Cancer Chronic Pain Pain Drug: Tapentadol Prolonged Release Phase 3

Detailed Description:

The prevalence of tumor-related pain is high and the treatment of chronic tumor-related pain remains a challenging therapeutic problem.

Participants directly entering the KF5503/52 trial from the KF5503/15 trial (i.e., within 7 days of Visit 8 of the KF5503/15 trial) is scheduled: a Transfer Visit, an Open-label Treatment Period and a Follow-up Period.

For participants with a gap of more than 7 days and less than 24 weeks, between their full completion of the KF5503/15 trial and entry into the KF5503/52 trial the following is scheduled: an Enrollment Visit, an Entry Visit for assessment of eligibility, an Open-label Treatment Period and a Follow-up Period.

This trial was designed to offer patients with chronic malignant tumor-related pain the option of continuing treatment by receiving tapentadol prolonged release (PR).

The protocol scheduled visits every 28 days during the open-label treatment period. Unscheduled visits (or at least unscheduled telephone calls) were planned when dose adjustment is required. If a visit is not possible at the time of dose change, it could be done up to 7 days later. Unscheduled visits could also be performed whenever considered necessary (i.e., for evaluation of adverse events).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol Prolonged Release (PR) in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.
Study Start Date : March 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tapentadol Prolonged Release
Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
Drug: Tapentadol Prolonged Release
Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
Other Names:
  • Nucynta®
  • Palexia®
  • Yantil®

Primary Outcome Measures :
  1. Severity of Adverse Events [ Time Frame: Day 1; up to 144 weeks ]

    The severity of treatment emergent adverse events was any untoward medical occurrence in a patient administered tapentadol. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the (investigational) medicinal product whether or not related to the use of tapentadol.

    The clinical "intensity" of adverse event were classified as:

    Mild: signs and symptoms which can be easily tolerated. Symptoms could be ignored and disappeared when the participant is distracted.

    Moderate: symptoms caused discomfort but were tolerable, they could not be ignored and affect concentration.

    Severe: symptoms affected the usual daily activity.

  2. Relatedness Assessment of Treatment Emergent Adverse Events [ Time Frame: Day 1; up to 144 weeks ]
    Participant-based analysis of treatment emergent adverse events (TEAEs) regarding the relationship to the study drug (tapentadol). The TEAEs were reported by the participants or were captured by the investigator. The relationship was rated by the investigator. The categorization of relatedness into one of the two categories was based on the following: Related included "possible", "probable/likely", and "certain"; whilst unrelated treatment emergent adverse events include those rated by the investigator as "unlikely", "conditional/unclassified", "un-assessable/unclassifiable", and "not related".

  3. Countermeasures Taken Due to Treatment Emergent Adverse Events [ Time Frame: Day 1; up to 144 weeks ]
    Participant-based analysis of treatment emergent adverse events (TEAEs) regarding countermeasure to the study drug (tapentadol). The TEAEs were reported by the participants or were captured by the investigator. The countermeasure taken by the investigator were reported.

  4. Time Dependence of Adverse Events [ Time Frame: Day 1; 144 weeks ]
    The onset and duration of TEAEs was not evaluated for this trial.

Secondary Outcome Measures :
  1. Assess Consumption of Tapentadol During Long Term Use [ Time Frame: Day 1; up to 144 weeks ]
    Summary of the modal total daily dose during the treatment period. The modal dose was based on assessment of the consecutive morning and evening intake amounts on each day and evaluation of the total daily dose.

  2. Tapentadol Prolonged Release Exposure [ Time Frame: Day 1; up to 144 weeks ]
    The number of days that participants took tapentadol prolonged release. The extent of exposure was categorized into 2 periods, less than 90 days and more than 90 days (up to 144 weeks).

Other Outcome Measures:
  1. Average Pain Intensity (Over a Twelve-week Period) [ Time Frame: Day 1; up to Week 144 ]

    The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Average pain intensity score is the average of pain experienced for previous 24 hours as rated on an 11-point NRS at each visit. Calculations are based on 3 consecutive planned (at 4-weekly intervals) visits.

    All available data of a participant was used; if a participant dropped-out or had incomplete data during a 12-week period no imputations were performed for the missing values.

  2. Average Daily Total Tapentadol Prolonged Release Dose [ Time Frame: Day 1; up to 144 weeks ]
    The Total Daily Dose (TDD) on any given day is the sum of the morning and evening intake amounts. The average TDD is an individuals average over the trial period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must have signed an Informed Consent Form.
  • At least 18 years of age.
  • Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control before entry and throughout the trial. Female participants of child-bearing potential must have a negative pregnancy test at enrollment.
  • Within 24 weeks of either full completion or completion of the double-blind treatment period (Visit 8) of KF5503/15 trial performed in participants with moderate to severe chronic malignant tumor related pain.
  • Participant is, in the opinion of the investigator, expected to continue to have an overall positive benefit/risk ratio from continuing analgesic treatment within this trial.
  • Participant must be willing to take tapentadol prolonged release (PR) throughout their participation in the trial.

Exclusion Criteria:

  • History of alcohol and/or drug abuse.
  • The participant has a clinically significant disease other than cancer that in the Investigator's opinion may affect the safety of the participant.
  • Employees of the investigator or trial center or family members of the employees or the investigator.
  • Known to or suspected of not being able to comply with the protocol and the use of tapentadol prolonged release (PR).
  • Concurrent participation in another trial (except for participation in the KF5503/15 trial) or planning to be enrolled in another clinical trial during the course of this trial.
  • Previous participation in another trial between the end of KF5503/15 and enrollment into the current trial, KF5503/52.
  • History of seizure disorder, epilepsy, traumatic brain injury, stroke or transient ischemic attack.
  • Known history and/or presence of cerebral tumors or metastases.
  • Rapidly escalating pain or pain uncontrolled by therapy and was previously treated with maximum dose level of Investigational Medicinal Product.
  • Participant is taking any prohibited concomitant medications.
  • Uncontrolled hypertension.
  • Known moderate or severe hepatic impairment.
  • Known severe renal impairment.
  • Clinically relevant history of hypersensitivity, allergy, or contraindications to tapentadol or its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01264887

Layout table for location information
Site 359004
Shumen, Bulgaria, 9700
Site 036002
Nyiregyhaza, Hungary, 4412
Site 036010
Szekszard, Hungary, 7100
Moldova, Republic of
Site 373001
Chisinau, Moldova, Republic of, 2025
Site 048004
Bydgoszcz, Poland, 85796
Site 048001
Warszawa, Poland, 02781
Site 040006
Brasov, Romania, 500074
Site 040002
Bucharest, Romania, 022328
Russian Federation
Site 007007
Nizhniy Novgorod, Russian Federation, 603140
Site 007012
Vladikavkaz, Russian Federation, 362007
Site 381002
Nis, Serbia, 18000
Site 381001
Sremska Kamenica, Serbia, 21204
Sponsors and Collaborators
Grünenthal GmbH
Layout table for investigator information
Principal Investigator: Hans-Georg Kress, Prof. Dr. med General Hospital Vienna
Layout table for additonal information
Responsible Party: Grünenthal GmbH Identifier: NCT01264887    
Other Study ID Numbers: KF5503/52
2009-013291-46 ( EudraCT Number )
168935 ( Other Identifier: Grünenthal GmbH )
First Posted: December 22, 2010    Key Record Dates
Results First Posted: June 22, 2015
Last Update Posted: November 4, 2019
Last Verified: October 2019
Keywords provided by Grünenthal GmbH:
chronic pain
tumour related pain
chronic malignant tumor-related pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Cancer Pain
Neurologic Manifestations
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents